Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) said its 30-milligram nimodipine tablets passed China's generic drug quality and efficacy consistency evaluation.
The drug is used to prevent and treat nerve damage caused by cerebral vasospasm after aneurysmal subarachnoid hemorrhage, according to a Monday filing on Hong Kong bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments